Exact Therapeutics ASto present at DNB Nordic Healthcare Conferenceon 16th December 2021 OSLO/ LONDON: 13 DECEMBER, 2021: Exact Therapeutics AS("EXACT-Tx", or "the Company" Euronext Growth: EXTX), a clinical-stage precision health company evaluating Acoustic Cluster Therapy (ACTÂ®) across multiple therapeutic areas, today announces that its Interim Chief Executive Officer and Chief Financial Officer, Dominic Morelandand Chief Medical Officer, Dr Hilary McElwaine-Johnnwill present a corporate overview via live webcast at the DNB Nordic Healthcare Conference 6th at 3:55pm CET. The Management Team is also available for 1:1 meetings with potential partners and investors. The presentation will be available at www.exact-tx.com. DNB is Norway'slargest financial services group and one of the largest in the Nordic region in terms of market capitalisation. The Group offers a full range of financial services, including loans, savings, advisory services, insurance and pension products for retail and corporate customers. END For more information, please contact: Dominic MorelandEXACT Therapeutics Email: [email protected] Optimum Strategic CommunicationsMary Clark/ Manel Mateus/ Vici Rabbets Tel: +44 (0) 208 078 0457 Email: [email protected] About EXACT EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACTÂ®). ACTÂ® follows a unique approach to ultrasound-mediated, targeted drug enhancement - with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and brain diseases. www.exact-tx.com About ACTÂ® oACTÂ® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent. oACTÂ® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration. oInitial focus of the Company is in oncology, however the ACTÂ® platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes.
Click here for more information
Â© Oslo Bors ASA, source